Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

by Bakris, George L, Agarwal, Rajiv, Anker, Stefan D, Pitt, Bertram, Ruilope, Luis M, Nowack, Christina, Kolkhof, Peter, Ferreira, Anna C, Schloemer, Patrick, Filippatos, Gerasimos, FIGARO-DKD investigators
Published 2023

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

by Pitt, Bertram, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Ruilope, Luis M, FIGARO-DKD investigators
Published 2023

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

by Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S. P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., FIDELIO-DKD Investigators.
Published 2022

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

by Anantharaman, Vathsala, Rossing, Peter, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M, Birkenfeld, Andreas L, McGill, Janet B, Rosas, Sylvia E, Joseph, Amer, Gebel, Martin, Roberts, Luke, Scheerer, Markus F, Bakris, George L, Agarwal, Rajiv
Published 2023

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

by Oshima, Megumi, Jardine, Meg J., Agarwal, Rajiv, Bakris, George, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Levin, Adeera, Lim, Soo Kun, Mahaffey, Kenneth W., Neal, Bruce, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Heerspink, Hiddo J. L.
Published 2021